Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Eur J Clin Invest 2012; 42 (7): 702–708 Background Postprandial accumulation of atherogenic remnants has been described in patients with type 2 diabetes mellitus (T2DM), familial combined hyperlipidaemia (FCH), familial hypercholesterolaemia (FH) and coronary artery disease (CAD). Scarce data are available on fasting plasma apolipoprotein (apo) B48 levels in relation to these conditions and atherosclerosis. Design Treated patients with FCH (18), FH (20), T2DM (26), CAD (65), T2DM with CAD (T2DM/CAD) (28) and 33 healthy controls were included. Intima‐media thickness (IMT) measurements were carried out to investigate subclinical atherosclerosis. Results LDL‐C and total apoB were lowest in patients with T2DM/CAD owing to the more frequent use of lipid‐lowering medication. Fasting plasma apoB48 was elevated in patients with FCH (11·38 ± 1·50 mg/L) and T2DM/CAD (9·65 ± 1·14 mg/L) compared with the other groups (anova, P < 0·01). CAD patients (8·09 ± 0·57 mg/L) had higher apoB48 levels than controls (5·74 ± 0·55 mg/L) and FH patients (5·40 ± 0·51 mg/L) (P = 0·02). IMT was highest in subjects with T2DM/CAD (0·77 ± 0·03 mm) (P < 0·01). The lowest IMT was measured in controls (0·56 ± 0·02 mm) and FCH patients (0·60 ± 0·03 mm). In the total group, the best association for apoB48 was found with fasting triglyceride (Pearson’s r = 0·72, P < 0·001). In the subjects not using statins (n = 74), the best correlation was found with IMT (r = 0·52; P < 0·001), whereas total apoB was not associated with IMT (r = 0·20, P = 0·12). Conclusions ApoB48 concentrations are highest in patients with FCH and in atherosclerotic subjects with T2DM. In patients not using statins, the surrogate atherosclerosis marker IMT correlates best with apoB48, suggesting that fasting apoB48 may help to detect subjects at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Weintraub, M. S., Eisenberg, S., & Breslow, J. L. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112926 · Cited by 261
Karpe, F., Boquist, S., Tang, R., Bond, G. M., de Faire, U., & Hamsten, A. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32331-2 · Cited by 174
Identification of lipoproteins of intestinal origin in human atherosclerotic plaque
Pal, S., Semorine, K., Watts, G. F., & Mamo, J. (2003) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2003.120 · Cited by 107
Cited by
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
“ApoB-48, the apolipoprotein present in chylomicrons and remnants, may serve as a surrogate marker of atherosclerosis in patients at risk (28).”
BackgroundArai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124
Postprandial lipaemia and vascular disease
Kolovou, G., & Ooi, T. C. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606971 · Cited by 32
Metadata
- Authors
- Alipour, A., Valdivielso, P., Elte, J. W. F., Janssen, H. W., Rioja, J., van der Meulen, N., van Mechelen, R., Njo, T. L., González‐Santos, P., Rietveld, A. P., & Cabezas, M. C.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2012-01-07
- Volume
- 42
- Issue
- 7
- Pages
- 702-708
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W1637179561
- Cited by
- 40
- References
- 7
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. https://app.cochat.ai/papers/10.1111/j.1365-2362.2011.02635.x
- The paper
- Alipour, A., Valdivielso, P., Elte, J. W. F., Janssen, H. W., Rioja, J., van der Meulen, N., van Mechelen, R., Njo, T. L., González‐Santos, P., Rietveld, A. P., & Cabezas, M. C. (2012). Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2011.02635.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.